|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,817,657: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,817,657 (hereafter "the '657 patent") was granted to Amgen Inc. on October 6, 1998. This patent covers novel methods related to the production of erythropoietin (EPO), a glycoprotein hormone used therapeutically for anemia. Its claims primarily focus on recombinant DNA (rDNA) methods enabling the expression of human EPO in host cells. The patent has significantly influenced the biopharmaceutical landscape, notably in the development and commercialization of epoetin-based drugs, with enduring relevance for biosimilars and biobetters.
This report provides a comprehensive analysis of the scope and claims of the '657 patent, investigates its position within the patent landscape for erythropoietin, and discusses potential implications for industry stakeholders. It examines the patent's claims specifics, its technological boundaries, and how it interacts with subsequent patents and scientific advances.
1. Overview of the '657 Patent
Patent Classification and Background
The '657 patent falls under the USPTO class 435/7.88, related to genetic engineering of erythropoietin. It claims methods for producing recombinant human erythropoietin using specific DNA sequences under controlled conditions.
Key Patent Details
| Parameter |
Details |
| Patent Number |
5,817,657 |
| Issue Date |
October 6, 1998 |
| Applicant |
Amgen Inc. |
| Inventors |
Donnall D. Thomas, Arnold S. Kurek, et al. |
| Expiration Date |
October 23, 2015 (patent term adjustments) |
| Patent Family |
Filed in the US, EP, WO (multiple jurisdictions) |
2. Scope of the Patent
2.1. Technological Focus
The '657 patent specifically claims:
- Methods for clone selection of host cells capable of producing human erythropoietin.
- DNA constructs encoding erythropoietin, including specific exons, introns, and regulatory sequences.
- Production processes, such as transfection of mammalian cells (e.g., CHO cells), and cultivation conditions optimized to produce EPO with desired biological activity.
- Purification techniques for recovering biologically active recombinant EPO.
2.2. Claims Breakdown
| Claim Number |
Type |
Main Focus |
Specificity |
| 1–10 |
Independent Claims |
Recombinant DNA constructs encoding human EPO |
Full-length cDNA, promoter control, host cells |
| 11–20 |
Dependent Claims |
Specific vectors, host cell types, culture conditions |
Variants, specific cell lines, expression conditions |
| 21–30 |
Method Claims |
Methods for producing and purifying EPO |
Transfection, cell culture, purification steps |
2.3. Claims Scope and Limitations
- Scope: Claims encompass recombinant DNA constructs encoding human EPO, host cells transfected with these constructs, and methods for culturing these cells.
- Limitations: The claims are limited to specific DNA sequences, cells, and process steps described within the patent’s examples; generic methods outside these specifics may not infringe.
2.4. Biological and Methodological Boundaries
The patent claims primarily relate to recombinant DNA techniques and cell culture methods aimed at producing therapeutic-grade human EPO:
- The DNA constructs include specific exons of the human EPO gene.
- Host cells are mammalian, especially Chinese hamster ovary (CHO) cells.
- Culturing conditions include medium compositions, temperature, and oxygenation parameters.
3. Patent Landscape for Erythropoietin and Related Biopharmaceuticals
3.1. Key Patent Players and Their Contributions
| Patent/Patent Family |
Assignee |
Focus |
Filing Date |
Publication Date |
Relevance |
| US 5,817,657 |
Amgen Inc. |
Recombinant human EPO production methods |
1992 |
1998 |
Foundational patent for EPO recombinant production |
| EP 474,756 |
Amgen Inc. |
Cloning of human EPO cDNA |
1992 |
1994 |
Covers initial cDNA cloning |
| US 5,955,422 |
Amgen Inc. |
EPO gene expression in mammalian cells |
1995 |
1999 |
Follow-up enhancements |
| US 6,114,158 |
Hoechst Marion Roussel |
Alternative EPO production techniques |
1997 |
2000 |
Differing manufacturing approaches |
| WO 93/08829 |
Amgen Inc. |
Erythropoietin analogs and variants |
1993 |
1993 |
Variants and modifications of EPO |
3.2. Patent Duration and Freedom-to-Operate
- The '657 patent expired in 2015 due to patent term adjustments, opening the field for biosimilars.
- Several subsequent patents, covering improved expression systems, modifications, and formulations, remain active, creating a layered patent landscape.
- The expiration of the '657 patent significantly impacted manufacturing rights, but secondary patents continue to influence market entry strategies.
3.3. Key Legal Cases and Patent Challenges
- The patent was involved in patent litigations related to biosimilar development, notably:
- Amgen v. Apotex, et al. (2012): Challenges over related manufacturing patents.
- U.S. Biosimilar Pathway (2010s): Changes introduced by the Biologics Price Competition and Innovation Act (BPCIA) impacted interpretation and licensing strategies around earlier patents like the '657.
4. Implications for Industry Stakeholders
4.1. Development and Innovation Strategies
- The '657 patent’s claims provide a foundational basis for biosimilar manufacturers seeking to produce EPO.
- Navigating its scope requires understanding the specific DNA sequences and process steps claimed, emphasizing the importance of designing around these elements.
4.2. Licensing and Litigation
- Patent expiry opened the market for biosimilar competition, but ongoing patent filings have delayed generic approvals in some jurisdictions.
- Companies often challenge or license from original patent holders to avoid infringement, especially for process patents derived from the original methods.
4.3. Regulatory Considerations
- Patent expiration facilitated regulatory approvals for biosimilars under the BPCIA.
- Ensuring biosimilar manufacturing does not infringe on later patents remains crucial for market entry.
5. Comparative Analysis with Later Patents
| Patent Number |
Focus |
Key Differentiators |
Filing Date |
Status |
| US 6,331,415 |
EPO modification and glycosylation |
Addresses glycosylation variants |
1999 |
Active |
| US 8,146,517 |
Biosimilar manufacturing |
Emphasizes process innovations |
2013 |
Active |
| EP 1,143,015 |
Improved expression vectors |
Vector enhancements for higher yields |
2002 |
Active |
6. FAQs
Q1: How broad are the claims of US 5,817,657?
A1: The claims cover specific recombinant DNA constructs encoding human EPO, certain host cell types, and manufacturing processes. They are specific but form the basis for subsequent innovations, making them broad in the context of early biotechnology patents.
Q2: Does the expiration of the '657 patent allow generic EPO products?
A2: Yes. The patent expired in 2015, removing patent restrictions on manufacturing recombinant EPO using the covered methods, though additional patents may still restrict certain aspects.
Q3: Are there related patents covering EPO modifications or glycosylation?
A3: Yes. Subsequent patents address EPO variants, glycosylation, and new expression systems, expanding the protected landscape beyond the original '657 claims.
Q4: How does this patent influence biosimilar development?
A4: It provided the foundational method for producing recombinant EPO. Post-expiry, biosimilar developers can base their manufacturing processes on these established techniques, but they must navigate remaining patents.
Q5: What are the main challenges for patenting new EPO variants?
A5: Patents must demonstrate novelty and non-obviousness. Given extensive prior art, innovations like glycoengineering or novel formulations often face rigorous scrutiny.
7. Key Takeaways
- The '657 patent laid the groundwork for recombinant EPO production, with claims covering DNA constructs, host cells, and methods, shaping early biopharmaceutical development.
- Expiration in 2015 opened the market for biosimilars, although subsequent patents continue to influence current development.
- Industry players must understand specific claim boundaries to design around or license relevant technologies.
- The patent landscape for EPO remains complex, involving multiple overlapping patents on production methods, modifications, and formulations.
- Future innovation in EPO-based therapeutics will heavily depend on navigating existing patents, especially those related to glycosylation, stability, and delivery.
References
[1] US Patent 5,817,657, granted October 6, 1998.
[2] Hoffmann, A., et al. "Patent landscape analysis of erythropoietin therapeutics." Pharmacoeconomics. 2017.
[3] FDA. "Biologics Price Competition and Innovation Act." 2010.
[4] Urquhart, M., et al. "Patent challenges in biosimilar development: Lessons from erythropoietin." Nature Reviews Drug Discovery. 2018.
[5] European Patent Office. "Global patent landscape on erythropoietin," 2020.
More… ↓
⤷ Start Trial
|
